REPLIGEN CORP Effective Income Tax Rate Reconciliation, Disposition of Asset, Amount
REPLIGEN CORP (RGEN) reported Effective Income Tax Rate Reconciliation, Disposition of Asset, Amount of -$5.63 million for the 3-month period ending 2017-09-30, per its 10-Q filed 2018-11-01.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationDispositionOfAssets · last filed 2018-11-01
- REPLIGEN CORP effective income tax rate reconciliation, disposition of asset, amount for the quarter ending 2017-09-30 was -$5.63M.
- REPLIGEN CORP effective income tax rate reconciliation, disposition of asset, amount for the quarter ending 2017-06-30 was -$5.63M.
| Period end | Effective Income Tax Rate Reconciliation, Disposition of Asset, Amount 3 month | Effective Income Tax Rate Reconciliation, Disposition of Asset, Amount 6 month |
|---|---|---|
| 2017-09-30 | -$5.63M 10-Q · filed 2018-11-01 | -$11.25M derived: sum of 2 quarters · filed 2018-11-01 |
| 2017-06-30 | -$5.63M 10-Q · filed 2018-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |